Xie, 30, married for two years without contraception, and his wife was not pregnant. Later, he went to the hospital for examination and found that he was a patient with oligospermia, and his wife did not detect abnormalities. Assisted reproduction was carried out at the suggestion of the doctor and the pregnancy was successful, but the embryo was stopped at the 5th week of pregnancy. Then he went to the hospital for genetic counseling, and the doctor suggested Xie to have a sperm DFI test. The results showed that the DFI of the period was as high as 50%. Xie carried out vitamin E antioxidant treatment at the suggestion of the doctor. Three months later, Xie went to the test of DFI again, and its DFI value fell to 12%. After assisted reproduction again, the wife successfully got pregnant and gave birth to a healthy baby.
Sperm nuclear integrity staining reagent products
During pregnancy, the main role of sperm is to provide its genetic material, namely sperm DNA, while semen routine can not complete the evaluation of sperm DNA quality. DFI analysis focuses on the genetic material of sperm, which can well evaluate the degree of sperm DNA damage, and then clarify the fertility of sperm. At present, many studies have confirmed that the correlation between semen analysis and testing results and DFI testing results is not high, that is, patients' semen routine testing results are normal, and their DFI testing results may still be abnormal. DFI detection mainly analyzes the proportion of sperm with sperm DNA damage through staining technology and flow cytometry sorting technology, which can effectively evaluate the subsequent pregnancy outcome.
Who benefits form DFI?
Male infertility population
Spousal recurrent abortion population
People planning assisted reproduction
Patients whose DFI test results were positive last time, and people who need to check DFI again after treatment
Pioneer original research
Cellpro Biotech is the first company in China to make DFI products. DFI products are independently developed by it. In 2016, it promoted the inclusion of DFI testing in the "guide for the diagnosis and treatment of male infertility"
since the product was launched in 2012, it has covered more than 300 medical institutions, with wide clinical application, good stability and high customer recognition
combined with patented devices, develop a live sperm eukaryotic test kit; Combined with artificial intelligence, ai-dfi products with higher sensitivity are developed
it can be adapted to more than a dozen commonly used flow cytometers, and the detection data of each platform are consistent.
Strict quality control
Cellpro Biotech has a strong quality control service system, which can ensure accurate and stable detection.